1. Gravholt CH, Andersen NH, Conway GS, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017; 177: G1–70. doi: 10.1530/EJE-17-0430.
2.
Gravholt CH, Hjerrild BE, Mosekilde L, et al. Body composition is distinctly altered in Turner syndrome: Relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol 2006; 155: 583–592. doi: 10.1530/eje.1.02267.
3.
O’Gorman CS, Syme C, Lang J, Bradley TJ, Wells GD, Hamilton JK. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome. Clin Endocrinol (Oxf) 2013; 78: 907–913. doi: 10.1111/cen.12079.
4.
Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998 Feb 1;51(2):147–158. doi: 10.1016/s0895-4356(97)00237-0.
5.
Caprio S, Boulware S, Diamond M, et al. Insulin Resistance: An Early Metabolic Defect of Turner’s Syndrome. J Clin Endocrinol Metab 1991; 72: 832–836. doi: 10.1210/jcem-72-4-832.
6.
Radetti G, Pasquino B, Gottardi E, et al. Insulin sensitivity in Turner's syndrome: influence of GH treatment. Eur J Endocrinol 2004; 151: 351–354. doi: 10.1530/eje.0.1510351.
7.
Błaszczyk E, Shulhai AM, Gieburowska J, et al. Components of the metabolic syndrome in girls with Turner syndrome treated with growth hormone in a long term prospective study. Front Endocrinol (Lausanne) 2023; 14: 1216464. doi: 10.3389/fendo.2023.1216464.
8.
Mondal S, Gargari P, Bose C, Garg MK, Chowdhury S, Mukhopadhyay S. Abnormal Body Composition Increases the Cardiometabolic Risk in Adolescents and Young Adults With Turner Syndrome. Endocr Pract 2024; 30: 259–269. doi: 10.1016/j.eprac.2023.11.013.
9.
Schoemaker MJ, Swerdlow AJ, Higgins CD, et al; United Kingdom Clinical Cytogenetics Group. Mortality in Women with Turner Syndrome in Great Britain: A National Cohort Study. J Clin Endocrinol Metab 2008; 93: 4735–4742. doi: 10.1210/jc.2008-1049.
10.
Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes 2012; 7: 284–294. doi: 10.1111/j.2047-6310.2012.00064.x.
11.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291–303. doi: 10.1136/adc.44.235.291.
12.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419. doi: 10.1007/BF00280883.
13.
Cutfield WS, Jefferies CA, Jackson WE, et al. Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children. Pediatr Diabetes 2003; 4: 119–125. doi: 10.1034/j.1399-5448.2003.t01-1-00022.x.
14.
Doknic M, Stojanovic M, Markovic A. Transition Period and Young Adulthood in Patients with Childhood Onset Growth Hormone Deficiency (COGHD): Impact of Growth Hormone Replacement on Bone Mass and Body Composition. Int J Mol Sci 2024; 25: 10313. doi: 10.3390/ijms251910313.
15.
Bengtsson BÅ, Brummer RJ, Bosaeus I. Growth Hormone and Body Composition. Horm Res 1990; 33 (Suppl. 4): 19–24. doi: 10.1159/000181579.
16.
Ferruzzi A, Vrech M, Pietrobelli A, et al. The influence of growth hormone on pediatric body composition: A systematic review. Front Endocrinol (Lausanne) 2023; 14: 1093691. doi: 10.3389/fendo.2023.1093691.
17.
Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2008; 93: 2109–2114. doi: 10.1210/jc.2007-2266.
18.
Gnacińska M, Magnuszewska H, Sworczak K. Metabolic consequences of recombinant human growth hormone therapy in patients with Turner syndrome. Pediatr Endocrinol Diabetes Metab 2022; 29: 16–21. doi: 10.5114/pedm.2022.123204.
19.
Gravholt CH, Naeraa RW, Brixen K, et al. Short-Term Growth Hormone Treatment in Girls With Turner Syndrome Decreases Fat Mass and Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Pediatrics 2002; 110: 889–896. doi: 10.1542/peds.110.5.889.
20.
Bannink EMN, van der Palen RLF, Mulder PGH, de Muinck Keizer-Schrama SMPF. Long-Term Follow-Up of GH-Treated Girls with Turner Syndrome: Metabolic Consequences. Horm Res Paediatr 2009; 71: 343–349. doi: 10.1159/000223419.
21.
Gravholt CH, Andersen NH, Christin-Maitre S, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2023 Aarhus International Turner Syndrome Meeting. Eur J Endocrinol 2024; 190: G1–G70. doi: 10.1530/EJE-17-0430.